HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

MABWELL-B

26.700

+1.1404.46%

Volume:1.07M

Turnover:28.64M

Market Cap:11.93B

PE:-9.49

High:27.440

Open:25.520

Low:25.200

Close:25.560

52wk High:31.460

52wk Low:20.800

Shares:447.00M

HK Float Shares:47.13M

Volume Ratio:1.50

T/O Rate:2.27%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-2.814

ROE:-118.88%

ROA:-11.80%

PB:96.49

PE(LYR):-9.49

PS:13.83

Loading ...

Overview Company News Filings

MABWELL-B Shares Surge Over 7% Following Clinical Trial Approval for Novel Inflammatory Bowel Disease Antibody

MABWELL-B Shares Surge Over 7% Against Market Trend Following Clinical Trial Approval

Mabwell Maintains Stable Share Base in May 2026; Confirms Public-Float Compliance

Bulletin Express

Mabwell gains NMPA green light for first-in-class antibody 9MW5211; IBD trial cleared in China and the U.S., MS filing accepted

Bulletin Express

Mabwell Receives Chinese Regulatory Nod for Clinical Trial of Investigational Drug 9MW5211

MABWELL-B Proposes New Executive Director Appointments

Mabwell Bioscience Releases Revised Articles of Association Detailing Governance, Capital Structure and Dividend Policy

Bulletin Express

MABWELL-B Shares Surge Over 6% on Upcoming ASCO Data Presentation for Key Drug Candidate

Mabwell to Present Latest Clinical Data for ADC 9MW2821 at 2026 ASCO Annual Meeting

Mabwell Gets Chinese Regulatory Nod to Expand Indication of Denosumab

MT Newswires Live

Mabwell's Injection Gains Approval for Expanded Use in Bone Metastasis and Multiple Myeloma Treatment

Mabwell Gets FDA Clearance for Inflammatory Bowel Disease Drug

MT Newswires Live

Mabwell-B Shares Surge Following FDA Clearance for Clinical Trial of Novel Drug Candidate

Mabwell Receives FDA Clearance for Clinical Trial of 9MW5211 Injection

Mabwell Bioscience Reports No Share Capital Changes in First Post-Listing Monthly Return

Bulletin Express

Mabwell (Shanghai) Bioscience Sets 1 June 2026 EGM to Approve Up to RMB1.00 Billion Targeted Debt Financing

Bulletin Express

Mabwell Announces Transition to Electronic Delivery of Corporate Communications

Bulletin Express

Mabwell seeks NAFMII nod for targeted debt financing of up to RMB1.00 billion

Bulletin Express

Mabwell to Implement Fully Digital Distribution of Shareholder Communications from 6 May 2026

Bulletin Express

MABWELL-B Plans to Issue Up to 1 Billion Yuan in Private Debt Financing Instruments

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/02493/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02493","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02493\",,,,,undefined,":{"symbol":"02493","market":"HK","secType":"STK","nameCN":"MABWELL-B","latestPrice":26.7,"timestamp":1781233140971,"preClose":25.56,"halted":0,"volume":1072200,"delay":0,"changeRate":0.044600938967136176,"floatShares":47130200,"shares":447000000,"eps":-2.813888632072146,"marketStatus":"Trading","change":1.14,"latestTime":"06-12 10:59:30","open":25.52,"high":27.44,"low":25.2,"amount":28639968,"amplitude":0.087637,"askPrice":26.7,"askSize":1400,"bidPrice":26.64,"bidSize":200,"shortable":0,"etf":0,"ttmEps":-2.6992487248395767,"tradingStatus":2,"nextMarketStatus":{"tag":"Noon Closed","tradingStatus":4,"beginTime":1781236800000},"marketStatusCode":2,"adr":0,"listingDate":1777305600000,"exchange":"SEHK","adjPreClose":25.56,"openAndCloseTimeList":[[1781227800000,1781236800000],[1781240400000,1781251200000]],"volumeRatio":1.495011,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688062","market":"SH","secType":"STK","nameCN":"Mabwell(Shanghai)Bioscience Co.,Ltd.","latestPrice":28.5,"timestamp":1781233166000,"preClose":27.23,"halted":0,"volume":5377400,"delay":0,"premium":"-19.10"}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02493\",,,,,undefined,":{"symbol":"02493","floatShares":47130200,"roa":"-11.80%","roe":"-118.88%","lyrEps":-2.813889,"volumeRatio":1.495011,"shares":447000000,"dividePrice":0,"high":27.44,"amplitude":0.087637,"preClose":25.56,"low":25.2,"week52Low":20.8,"pbRate":"96.49","psRate":"13.83","week52High":31.46,"institutionHeld":0,"latestPrice":26.7,"committee":-0.75,"eps":-2.813888632072146,"divideRate":0,"volume":1072200,"delay":0,"ttmEps":-2.6992487248395767,"open":25.52,"prevYearClose":27.64,"prevWeekClose":22.4,"prevMonthClose":22.78,"prevQuarterClose":27.64,"fiveDayClose":22.4,"twentyDayClose":25.38,"sixtyDayClose":27.64},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02493\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02493\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02493\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":1,"buy":0,"hold":0,"sell":0,"strongSell":0,"meanLabel":"STRONG BUY","meanPercent":1,"analysts":1,"updateTime":1772035200000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02493\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02493","date":"2026-06-11","current":-9.663803,"percent":0.823529,"low":-17.302507,"twenty":-16.533336,"median":-15.517615,"eighty":-13.271127,"high":-12.171256,"avg":-15.062017,"sd":1.494762,"marketCap":13752401159.16},"quantilePoints":[{"date":"2026-04-24","current":-15.289641,"twenty":-16.199622,"median":-15.659552,"eighty":-15.437605,"marketCap":17000217748.15},{"date":"2026-04-30","current":-16.640195,"twenty":-16.379645,"median":-15.593679,"eighty":-15.250239,"marketCap":17562577595.07},{"date":"2026-05-08","current":-16.416983,"twenty":-16.631559,"median":-16.471868,"eighty":-15.350449,"marketCap":17380742435.69},{"date":"2026-05-15","current":-16.009725,"twenty":-16.685787,"median":-16.416983,"eighty":-15.606854,"marketCap":16994157190.87},{"date":"2026-05-22","current":-15.517615,"twenty":-16.631559,"median":-16.0746,"eighty":-15.529829,"marketCap":16434142933.1},{"date":"2026-05-29","current":-14.179755,"twenty":-16.597014,"median":-15.628209,"eighty":-15.240388,"marketCap":15069483633.31},{"date":"2026-06-05","current":-12.517432,"twenty":-16.559668,"median":-15.581594,"eighty":-14.26556,"marketCap":13322161865.15},{"date":"2026-06-11","current":-12.930428,"twenty":-16.533336,"median":-15.517615,"eighty":-13.271127,"marketCap":13752401159.16}],"updateTime":1781228768685},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02493\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1179539839","title":"MABWELL-B Shares Surge Over 7% Following Clinical Trial Approval for Novel Inflammatory Bowel Disease Antibody","url":"https://stock-news.laohu8.com/highlight/detail?id=1179539839","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1179539839?lang=en_us&edition=fundamental","pubTime":"2026-06-11 14:43","pubTimestamp":1781160222,"startTime":"0","endTime":"0","summary":"MABWELL-B (HKEX: 02493) shares have surged more than 7% in today's trading session. At the time of writing, the stock is up 5.71%, trading at HK$25.9 with a turnover of HK$48.537 million. Key...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK4588","VXUS","BK4585","02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1123729715","title":"MABWELL-B Shares Surge Over 7% Against Market Trend Following Clinical Trial Approval","url":"https://stock-news.laohu8.com/highlight/detail?id=1123729715","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1123729715?lang=en_us&edition=fundamental","pubTime":"2026-06-10 10:12","pubTimestamp":1781057543,"startTime":"0","endTime":"0","summary":"Shares of MABWELL-B (02493) have risen more than 7%, moving against the broader market trend.As of the latest update, the stock is up 6.54% to HK$23.78, with a trading volume of HK$8.6025 million.The...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","VXUS","BK4588","02493","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1146597371","title":"Mabwell Maintains Stable Share Base in May 2026; Confirms Public-Float Compliance","url":"https://stock-news.laohu8.com/highlight/detail?id=1146597371","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1146597371?lang=en_us&edition=fundamental","pubTime":"2026-06-05 08:03","pubTimestamp":1780617784,"startTime":"0","endTime":"0","summary":"Mabwell (Shanghai) Bioscience Co., Ltd. (Mabwell) filed its Monthly Return for Equity Issuer for the period ended 31 May 2026, confirming that no changes occurred in either its authorised or issued...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114470341","title":"Mabwell gains NMPA green light for first-in-class antibody 9MW5211; IBD trial cleared in China and the U.S., MS filing accepted","url":"https://stock-news.laohu8.com/highlight/detail?id=1114470341","media":"Bulletin Express","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1114470341?lang=en_us&edition=fundamental","pubTime":"2026-06-04 21:24","pubTimestamp":1780579497,"startTime":"0","endTime":"0","summary":"Mabwell (Shanghai) Bioscience Co., Ltd. announced that China’s National Medical Products Administration has approved a clinical trial application for 9MW5211 injection in inflammatory bowel disease...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1167249178","title":"Mabwell Receives Chinese Regulatory Nod for Clinical Trial of Investigational Drug 9MW5211","url":"https://stock-news.laohu8.com/highlight/detail?id=1167249178","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1167249178?lang=en_us&edition=fundamental","pubTime":"2026-06-04 18:12","pubTimestamp":1780567949,"startTime":"0","endTime":"0","summary":"Mabwell (Shanghai) Bioscience Co., Ltd. (ASX: 688062), also known as Mabwell-B (ASX: 02493), has announced that its clinical trial application for the investigational drug 9MW5211 injection has...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688062","BK0239","02493","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168787822","title":"MABWELL-B Proposes New Executive Director Appointments","url":"https://stock-news.laohu8.com/highlight/detail?id=1168787822","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1168787822?lang=en_us&edition=fundamental","pubTime":"2026-05-31 20:00","pubTimestamp":1780228827,"startTime":"0","endTime":"0","summary":"MABWELL-B (02493) has announced that its second-term board of directors was elected at the company's 2022 annual general meeting on April 27, 2023. The term for this board will run from June 21,...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02493","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124612640","title":"Mabwell Bioscience Releases Revised Articles of Association Detailing Governance, Capital Structure and Dividend Policy","url":"https://stock-news.laohu8.com/highlight/detail?id=1124612640","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1124612640?lang=en_us&edition=fundamental","pubTime":"2026-05-29 22:44","pubTimestamp":1780065852,"startTime":"0","endTime":"0","summary":"Mabwell (Shanghai) Bioscience Co., Ltd. (“Mabwell Bioscience”) has published an updated Articles of Association (effective May 2026), outlining key corporate governance mechanisms, share capital...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1173177905","title":"MABWELL-B Shares Surge Over 6% on Upcoming ASCO Data Presentation for Key Drug Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=1173177905","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1173177905?lang=en_us&edition=fundamental","pubTime":"2026-05-22 09:52","pubTimestamp":1779414744,"startTime":"0","endTime":"0","summary":"MABWELL-B (02493) rose more than 6%. At the time of writing, the stock was up 5.22% to HKD 25.8, with a turnover of HKD 7.1328 million. The company announced that it will present the latest clinical...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02493","BK1161","BK4585","VXUS","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187250283","title":"Mabwell to Present Latest Clinical Data for ADC 9MW2821 at 2026 ASCO Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=1187250283","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1187250283?lang=en_us&edition=fundamental","pubTime":"2026-05-21 17:21","pubTimestamp":1779355318,"startTime":"0","endTime":"0","summary":"Mabwell (Shanghai) Bioscience Co., Ltd. has announced that it will present clinical data for its targeted Nectin-4 ADC novel drug, 9MW2821 (Bulumtatug Fuvedotin, BFv), at the 2026 American Society of...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0239","688062","BK1161","02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637053928","title":"Mabwell Gets Chinese Regulatory Nod to Expand Indication of Denosumab","url":"https://stock-news.laohu8.com/highlight/detail?id=2637053928","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637053928?lang=en_us&edition=fundamental","pubTime":"2026-05-21 11:16","pubTimestamp":1779333367,"startTime":"0","endTime":"0","summary":"Mabwell  Bioscience  said Chinese regulators expanded denosumab's approval to include new indications, according to a Wednesday filing with the Hong Kong bourse.The firm's Hong Kong shares gained nearly 4% in morning trade Thursday.Denosumab, also known as maiweijian and 9MW0321, will now be available to treat bone metastases from solid tumors and to delay or reduce the risk of skeletal-related events in patients with multiple myeloma.The medicine, a biosimilar version of Xgeva, was previously approved in China to treat giant cell tumor of the bone.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["688062","BK0239","BK1161","02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135264718","title":"Mabwell's Injection Gains Approval for Expanded Use in Bone Metastasis and Multiple Myeloma Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=1135264718","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1135264718?lang=en_us&edition=fundamental","pubTime":"2026-05-20 16:40","pubTimestamp":1779266432,"startTime":"0","endTime":"0","summary":"Mabwell (Shanghai) Bioscience Co., Ltd. (688062.SH) announced that its wholly-owned subsidiary, Jiangsu Taikang Biological Medicine Co., Ltd., has received approval from the National Medical Products...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["688062","BK1161","02493","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634477456","title":"Mabwell Gets FDA Clearance for Inflammatory Bowel Disease Drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2634477456","media":"MT Newswires Live","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2634477456?lang=en_us&edition=fundamental","pubTime":"2026-05-11 14:20","pubTimestamp":1778480432,"startTime":"0","endTime":"0","summary":"Mabwell  Bioscience's  clinical trial application for 9MW521, a novel injection targeting Inflammatory Bowel Disease , was formally cleared by the US Food and Drug Administration, according to a May 8 Hong Kong bourse filing.Shares of the pharmaceutical firm were up nearly 4% in Monday afternoon trading.The drug will be tested as a treatment for inflammatory bowel disease.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"f6f7c9f6a0174df79daf9f1dfd21f836","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4588","LABU","IBD","BK0239","02493","BK4585","688062","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187988475","title":"Mabwell-B Shares Surge Following FDA Clearance for Clinical Trial of Novel Drug Candidate","url":"https://stock-news.laohu8.com/highlight/detail?id=1187988475","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1187988475?lang=en_us&edition=fundamental","pubTime":"2026-05-11 14:00","pubTimestamp":1778479227,"startTime":"0","endTime":"0","summary":"Mabwell-B (02493) saw its shares rise nearly 5% in the afternoon session. At the time of writing, the stock was up 3.54%, trading at HKD 27.52 with a turnover of HKD 33.26 million. The increase...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LABU","BK1161","BK1574","BK4585","VXUS","BK0239","06978","159992","688062","02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1120526047","title":"Mabwell Receives FDA Clearance for Clinical Trial of 9MW5211 Injection","url":"https://stock-news.laohu8.com/highlight/detail?id=1120526047","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1120526047?lang=en_us&edition=fundamental","pubTime":"2026-05-08 18:20","pubTimestamp":1778235634,"startTime":"0","endTime":"0","summary":"Mabwell (688062.SH) announced that it has received a Study May Proceed notification from the U.S. Food and Drug Administration (FDA), granting official approval for the clinical trial application of...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","LABU","BK0239","688062","BK4588","02493","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1108460780","title":"Mabwell Bioscience Reports No Share Capital Changes in First Post-Listing Monthly Return","url":"https://stock-news.laohu8.com/highlight/detail?id=1108460780","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1108460780?lang=en_us&edition=fundamental","pubTime":"2026-05-07 20:04","pubTimestamp":1778155467,"startTime":"0","endTime":"0","summary":"Mabwell (Shanghai) Bioscience Co., Ltd. (abbrev. Mabwell Bioscience) has released its inaugural Monthly Return for the period ended 30 April 2026 following the company’s Main Board debut on the Hong...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1127675446","title":"Mabwell (Shanghai) Bioscience Sets 1 June 2026 EGM to Approve Up to RMB1.00 Billion Targeted Debt Financing","url":"https://stock-news.laohu8.com/highlight/detail?id=1127675446","media":"Bulletin Express","labels":["corporation","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1127675446?lang=en_us&edition=fundamental","pubTime":"2026-05-06 23:02","pubTimestamp":1778079764,"startTime":"0","endTime":"0","summary":"Mabwell (Shanghai) Bioscience Co., Ltd. (MABWELL-B) has called its 2026 second extraordinary general meeting (EGM) for 3:00 p.m. on Monday, 1 June 2026 at Conference Room 103, Building 3, Chuangxiang...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128854163","title":"Mabwell Announces Transition to Electronic Delivery of Corporate Communications","url":"https://stock-news.laohu8.com/highlight/detail?id=1128854163","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1128854163?lang=en_us&edition=fundamental","pubTime":"2026-05-06 22:42","pubTimestamp":1778078579,"startTime":"0","endTime":"0","summary":"On 6 May 2026 Mabwell (Shanghai) Bioscience Co., Ltd. announced that all future corporate communications—including annual and interim reports, circulars, meeting notices and proxy forms—will be...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1135676279","title":"Mabwell seeks NAFMII nod for targeted debt financing of up to RMB1.00 billion","url":"https://stock-news.laohu8.com/highlight/detail?id=1135676279","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1135676279?lang=en_us&edition=fundamental","pubTime":"2026-05-06 22:42","pubTimestamp":1778078576,"startTime":"0","endTime":"0","summary":"Mabwell (Shanghai) Bioscience Co., Ltd. announced that its board approved an application to the National Association of Financial Market Institutional Investors (NAFMII) for the registration and...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1125424148","title":"Mabwell to Implement Fully Digital Distribution of Shareholder Communications from 6 May 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=1125424148","media":"Bulletin Express","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1125424148?lang=en_us&edition=fundamental","pubTime":"2026-05-06 22:22","pubTimestamp":1778077369,"startTime":"0","endTime":"0","summary":"Mabwell (Shanghai) Bioscience Co., Ltd. has announced that, with effect from 6 May 2026, all future corporate communications to shareholders will transition to electronic delivery in compliance with...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02493"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1126415861","title":"MABWELL-B Plans to Issue Up to 1 Billion Yuan in Private Debt Financing Instruments","url":"https://stock-news.laohu8.com/highlight/detail?id=1126415861","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1126415861?lang=en_us&edition=fundamental","pubTime":"2026-05-06 22:12","pubTimestamp":1778076735,"startTime":"0","endTime":"0","summary":"MABWELL-B (02493) has announced its intention to apply for the registration and issuance of private debt financing instruments with a total value not exceeding 1 billion yuan (inclusive). The move...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02493","BK0239","688062","BK1161"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":41,"code":"91000000","status":"200"}]}}